Jump to content
  • rrdiLogo384x64.jpg

    We are rosaceans and this is a grassroots rosacea non profit organization. Finding the Cure for rosacea. If you like to read, scroll down to the bottom. If you prefer videos, scroll down to view all the videos about the RRDi. What's with the butterfly? We need 100 Active Subscribers! To learn more about the RRDi watch the videos by scrolling below, or if you prefer reading, keep scrolling. If you want to change how the RRDi is run, why not volunteer to post (subscription fees waived for volunteers) and tell us what you think the RRDi should be doing. 

    Join the most private rosacea community on the web!

    Videos & RRDi Social Media Accounts

  • Forum Statistics

    • Total Topics
      6.5k
    • Total Posts
      8.2k
  • The Rosacea Research & Development Institute [RRDi] is the first 501 (c) (3) non profit organization approved by the IRS established June 7, 2004 in the State of Hawaii, USA for the purpose of finding a cure for rosacea, researching rosacea, and to form a rosacea patient advocacy organization established by volunteer rosaceans for rosacea sufferers. In December 2019 we have moved the corporate office to the State of Alabama and have registered as a non profit corporation.

    Our non profit organization for rosacea patient advocacy web site is a digital data repository of rosacea information that can serve you personally as an armamentarium of rosacea treatment options. We have tools to help you in your search for a cure to rosacea, or at least a way to control it.

    We have chosen the Invision Community as the chief digital platform tool (with beta versions for Android and iOS mobile apps) to use, a public platform for guests and inactive members. Our member forum is the most private forum for rosacea on the internet. We also have a private platform using Tapatalk using our rosacea-control.com domain. 

    We are rosacea sufferers [rosaceans] and all are volunteers. We rely on donations. No one is receiving a salary or getting paid. We don't spend donated funds on private contractors that are owned by any member of the board of directors. We do not spend donated funds so our members can attend dermatology conventions. All donations are spent on keeping this non profit organization for rosacea sufferers a viable patient advocacy organization and our rules state that 'members may not profit from the institute' (rule number 3). Read our mission statement

    No one has a paid salary, we pay NO private contractors nor do we use donations so our members can attend dermatology conventions. 

    All the other rosacea non profits are not run by rosacea sufferers (see Other Non Profit Rosacea Organizations on this page). Check out the other non profit organizations for rosacea, discover for yourself and you will find out who serve on the board of directors (non rosaceans - dermatologists/businessmen) and then simply follow the money (what does the organization spend most of the donated money on?) and discover for yourself that the other non profit organizations for rosacea spend most of the donations on (1) private contractors, (2) dermatologist member conventions or (3) salaries. We have no special interest other than finding the cure for rosacea and forming a rosacea patient advocacy organization. Our non profit has no salaries, no spending on private contractors, no expenses for member conventions. Follow the money (this is where we spend our money). Notice where most of the money is spent with another rosacea non profit, who has spent millions of dollars on private contractors owned by the president of the non profit and only 10% on rosacea research. 

    Read our Misson Statement and see if you agree? If you suffer from rosacea, this is the rosacea non profit to join. Your membership increases our impact on the medical community. Our goal is to reach 10,000 members. Please join and help us reach our goal. What if 10,000 members got together and each donated one dollar and all the members agreed we should sponsor a certain rosacea research study. Is this possible? Only with your help. 

    You may want to read our post about Anonymity, Transparency and Posting before joining. We have now switched to a subscription member service

    The logo of the RRDi includes a butterfly because rosacea typically manifests itself in a facial butterfly formation, however the irony of the butterfly effect is apropros. Learn More.

    You may want to learn about the history of this non profit or why it was formed

    If you are a rosacean, volunteer by joining our private member forum and posting or in our public guest forum (registration required) becoming a part of 'finding the cure' for rosacea if you join. Our goal is 10,000 members. Membership is free. You can help us reach our goal by joining with just your email address.  if privacy is of paramount importance to you use Sign in with Apple and join our private member forum. Or you can simply browse our web site and guest forum for free. Our non profit affiliate store is another source of rosacea treatment options. 

    If you want to post about your rosacea, we certainly allow you to post feedback in our GUEST forum or register an account in our member forum, i.e,, in our public community support, and, if you want to learn about and treat your rosacea, this is the best non profit organization for rosacea sufferers. At the social networks like Facebook, Instagram or Reddit can you find the incredible digital tools the RRDi provides free to its members or the ability to find what you are searching for in rosacea research? Are you able through such social media groups to influence the medical community how you feel about rosacea? Read our mission statement and compare with your private rosacea social media group, i.e., like Facebook, Instagram or Reddit.  

    The RRDi is registered at GuideStar and Trustpilot • Write a Review of Our Non Profit

  • Member Statistics

    1,675
    Total Members
    499
    Most Online
    Richard Trafford-Owen
    Newest Member
    Richard Trafford-Owen
    Joined


  • Registered with the USA Internal Revenue Service

    IRSlogo.png

    EIN 20-1259275

  • 240px-Seal_of_Alabama.svg.png

  • Alabama Secretary of State Certification

    Entity Identification Number 596-247

  • Guest Signup

    Show your support for the RRDi

  • Posts

    • Skin Res Technol. 2024 Mar;30(3):e13616. doi: 10.1111/srt.13616. ABSTRACT OBJECTIVE: To investigate the life, sleep quality and anxiety of rosacea patients in Yunnan and the improvement of these aspects after treatment. METHODS: A total of 141 patients with rosacea and 123 healthy controls were included in our study. The quality of life, sleep quality and anxiety of patients with rosacea and healthy controls were investigated by the Rosacea Severity Scores (RSSs), the Medical Outcomes Study 36-item short-form health survey (SF-36), the Pittsburgh Sleep Quality Index (PSQI) and Self-rating Anxiety Scale (SAS). The quality of life, sleep quality and anxiety of patients with rosacea were assessed again after treatment. RESULTS: Compared with healthy controls, patients with rosacea had significantly lower physical component scores (PCS) and mental component scores (MCS) but higher PSQI and SAS scores. After treatment, rosacea patients showed significantly higher MCS but lower PSQI and SAS scores. Correlation analysis showed a significant correlation between PCS, MCS, PSQI, SAS and RSSs. CONCLUSIONS: Patients with rosacea have a lower quality of life and sleep quality and tend to be more anxious than healthy controls. In addition, the mental quality of life, sleep quality and anxiety of rosacea patients can be significantly improved after treatment. Therefore, it is important to pay attention to the psychological status of rosacea patients. Psychological counseling and intervention are necessary to better prevent and treat rosacea. PMID:38424730 | DOI:10.1111/srt.13616 {url} = URL to article
    • Int J Dermatol. 2024 Mar 1. doi: 10.1111/ijd.17114. Online ahead of print. NO ABSTRACT PMID:38429862 | DOI:10.1111/ijd.17114 {url} = URL to article
    • Australas J Dermatol. 2024 Feb 28. doi: 10.1111/ajd.14224. Online ahead of print. ABSTRACT BACKGROUND: Atrophic acne scarring is a common sequela of inflammatory acne, causing significant problems for affected patients. Although prolonged inflammation and subsequent aberrant tissue regeneration are considered the underlying pathogenesis, the role of epidermal stem cells, which are crucial to the regeneration of pilosebaceous units, remains unknown. OBJECTIVES: To examine the changes occurring in epidermal stem cells in atrophic acne scars. METHODS: Changes in collagen, elastic fibre and human leukocyte antigen (HLA)-DR expression were analysed in normal skin and inflammatory acne lesions at days 1, 3 and 7 after development. The expression of epidermal stem cell markers and proliferation markers was compared between normal skin and mature atrophic acne scar tissue. RESULTS: In acne lesions, inflammation had invaded into pilosebaceous units over time. Their normal structure had been destructed and replaced with a reduced amount of collagen and elastic fibre. Expression of stem cell markers including CD34, p63, leucine-rich repeat-containing G protein-coupled receptor (LGR)6 and LGR5, which are expressed in the interfollicular epidermis, isthmus and bulge of hair follicles, significantly decreased in atrophic acne scar tissue compared to normal skin. Epidermal proliferation was significantly reduced in scar tissue. CONCLUSIONS: These findings suggest that as inflammatory acne lesions progress, inflammation gradually infiltrates the pilosebaceous unit and affects the resident stem cells. This disruption impedes the normal regeneration of the interfollicular epidermis and adnexal structures, resulting in atrophic acne scars. PMID:38419202 | DOI:10.1111/ajd.14224 {url} = URL to article
    • J Dermatol. 2024 Feb 29. doi: 10.1111/1346-8138.17168. Online ahead of print. ABSTRACT Rosacea is a chronic inflammatory skin disease. Systemic inflammation plays a vital role in the pathogenesis of rosacea. Many studies have reported hematological parameters as biomarkers for diseases with inflammatory processes. However, the diagnostic value of hematological parameters in rosacea remains a puzzle. This study involved 462 patients with rosacea, including erythematotelangiectatic rosacea (ETR, n = 179), papulopustular rosacea (PPR, n = 250), and phymatous rosacea (PhR, n = 33), and 924 healthy control subjects. Demographic, clinical, and laboratory information was collected and compared between rosacea subtypes. The hematological parameters of the patients and the healthy controls were compared retrospectively. The platelet volume (MPV) and platelet crit (PCT) were significantly upregulated, and the lower red cell distribution width (RDW) was significantly downregulated in rosacea compared to healthy controls, and they were identified as the diagnostic biomarkers for rosacea with area under the curve values of 0.828, 0.742, and 0.787, respectively. Comparing the hematological parameters among the three rosacea subtypes, we found that platelet-to-lymphocyte ratio and platelet-to-neutrophil ratio values in the ETR group were significantly higher than those in the PPR and PhR groups. The correlation between hematological parameters and clinical scores showed that RDW was negatively correlated with the Clinician Erythema Assessment score. However, there was no significant correlation between the Investigator Global Assessment score and hematological parameters. In conclusion, PCT, MPV, and RDW have diagnostic value for rosacea, and RDW is correlated with the severity of rosacea erythema, implying the potential applications of PCT, MPV, and RDW in the diagnosis and monitoring of rosacea. PMID:38421898 | DOI:10.1111/1346-8138.17168 {url} = URL to article
    • Med Mycol J. 2024;65(1):23-26. doi: 10.3314/mmj.23-00014. ABSTRACT A Filipino woman in her forties had facial erythema that was being self-treated with over-the-counter (OTC) drugs purchased outside of Japan. The drugs included clobetasol propionate, antibiotic, and antifungal components. Her facial erythema symptoms were worse during summertime. KOH direct examination of annular erythema was positive for fungal hyphae and negative for Demodex folliculorum. Fungal culture revealed Trichophyton indotineae based on internal transcribed spacer sequence analysis. Minimal inhibitory concentration for terbinafine was 0.06 µg/mL. We made a diagnosis of tinea faciei with steroid rosacea. We treated the patient with oral itraconazole. Physicians should be aware of increasing T. indotineae infections and increasing self-medication using topical OTC steroids combined with antifungals and antibiotics not only in India but also among foreign people living in other countries such as Japan. PMID:38417884 | DOI:10.3314/mmj.23-00014 {url} = URL to article
    • Drugs. 2024 Feb 29. doi: 10.1007/s40265-024-02003-w. Online ahead of print. ABSTRACT Rosacea, a chronic skin condition affecting millions of people in the USA, leads to significant social and professional stigmatization. Effective management strategies are crucial to alleviate symptoms and improve patients' quality of life. Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment for rosacea that shows promise in enhancing therapeutic response and minimizing skin irritation. This review aims to assess the role of recently FDA approved E-BPO 5% in the current treatment landscape for rosacea management, as it is not yet included in clinical guidelines that predominantly rely on older approved therapies. The review focuses on randomized controlled trials conducted in English-speaking adults. It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream. Existing therapies have been effective in reducing papulopustular lesions and erythema associated with rosacea for many years. E-BPO 5% offers a promising addition to the treatment options due to its microencapsulation technology, which prolongs drug delivery time and aims to improve therapeutic response while minimizing skin irritation. Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment. PMID:38418773 | DOI:10.1007/s40265-024-02003-w {url} = URL to article
    • This is an example of clinicians who still rely on the Subtype classification of rosacea which was abandoned several years ago. ETR is subtype 1. The new classification of rosacea into phenotypes separates this subtype into two phenotypes:  (2) Persistent Erythema (3) Telangiectasia Dapsone has been used to treat Granulomatous Rosacea [also known as Lupoid rosacea] [1] as well as PPR [2] [1] Hautarzt. 2013 Apr;64(4):226-8. doi: 10.1007/s00105-013-2556-7. Successful treatment of granulomatous rosacea with dapsone. Ehmann LM, Meller S, Homey B. Hautklinik des Universitätsklinikums Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland. PubMed RSS Feed - - Dapsone  for Unresponsive Granulomatous Rosacea. [2] Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double-Blind Randomized Clinical Trial.        
    • Pediatr Dermatol. 2024 Feb 27. doi: 10.1111/pde.15571. Online ahead of print. ABSTRACT BACKGROUND: Idiopathic aseptic facial granuloma (IAFG) is an underrecognized pediatric skin disease, currently considered within the spectrum of rosacea. It usually manifests as a solitary, reddish, asymptomatic nodule on the cheek that resolves spontaneously. METHODS: Retrospective and descriptive observational study of 43 pediatric patients with a clinical diagnosis of IAFG, followed between 2004 and 2022, at two general hospitals in Argentina. RESULTS: IAFG predominated in girls (65%) and the average age of onset was about 6 years. A single asymptomatic nodule was seen in 79% of patients. The most common localization was the cheek (58%) followed by lower eyelids (41%). Family history of rosacea was present in 16% of patients. A concomitant diagnosis of rosacea and periorificial dermatitis was made in 14% and 9% of our population, respectively. Past or present history of chalazia was detected in 42% of the children. IAFG diagnosis was mainly clinical (88% of cases). Oral antibiotics were the most common indicated treatment (84%). Complete healing was achieved by the majority, but 18% of those with eyelid compromise healed with scars. CONCLUSIONS: IAFG is a benign pediatric condition that physicians should recognize in order to manage correctly. We herein refer to a particular morphologic aspect of IAFG lesions affecting the lower eyelids, where nodules adopt a linear distribution and have a higher probability of involute leaving a scar. Also, we consider that the concomitant findings of rosacea, periorificial dermatitis and chalazia in our patients, reinforce the consideration of IAFG within the spectrum of rosacea. PMID:38413004 | DOI:10.1111/pde.15571 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use